GlassScriptPhysician profile
Benjamin W Goodman, JR.
NPI 1801986872
$4,092.94
in general payments reported to CMS, 2019-2025
33 companies · $16.32 in 2025
The $16.32 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $714 · 2021: $725 · 2022: $1,264 · 2023: $411 · 2024: $56.17 · 2025: $16.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $468.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $605.66 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $539.19 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $401.14 | 2019-2022 | |
| Glaxosmithkline, LLC. | $339.34 | 2019-2023 | Bexsero, Shingrix, Trelegy Ellipta |
| Lilly USA, LLC | $233.12 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Dexcom, INC. | $197.55 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $192.82 | 2019-2023 | |
| Amgen INC. | $189.75 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $172.11 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $166.75 | 2019-2023 | Breztri |
| Amarin Pharma, INC. | $136.24 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.94 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.01 | 2019-2023 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $75.76 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.72 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $71.33 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.42 | 2019-2021 | |
| Abbott Laboratories | $58.83 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.06 | 2021-2022 | |
| Zyla Life Sciences, INC. | $44.55 | 2019-2020 | |
| Allergan, INC. | $41.25 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $40.79 | 2022 | |
| Janssen Pharmaceuticals, INC | $35.91 | 2019-2021 | |
| Astellas Pharma US INC | $29.76 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $25.71 | 2021 | |
| Ge Healthcare | $18.91 | 2020 | |
| Ibsa Pharma INC. | $18.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.92 | 2022 | |
| Eisai INC. | $14.94 | 2021 | |
| Exact Sciences Corporation | $14.39 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $12.66 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.10 | 2019 | |
| Mylan Specialty L.P. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Goodman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.